AUTHORS
Xianbo Huang, MD, Ying Chen, MD2, Xianhui Wu3, Shasha Wang, MD4, Yanling Ren5, Chen Mei6, Yu Xu7, Jie Jin, MD8, Hongyan Tong, MD, PhD9, Jiejing Qian10
AFFILIATIONS
1 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
3 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
4 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
5 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
6 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
7 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
8 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
9 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
10 The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
ABSTRACT
Background:
Intestinal acute graft-versus-host disease (aGVHD) remains a major cause of nonrelapse mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We investigated whether acyl-CoA synthetase long-chain family member 4 (ACSL4)-associated ferroptosis links alloimmune inflammation to intestinal tissue injury and represents a therapeutically targetable pathway.
Methods:
We used a fully MHC-mismatched C57BL/6-to-BALB/c allo-HSCT model, in which aGVHD was induced by co-infusing donor splenocytes with donor bone marrow cells. We integrated intestinal bulk RNA sequencing, biochemical assays, quantitative PCR, immunoblotting, immunohistochemistry, transmission electron microscopy, and single-cell RNA sequencing (scRNA-seq). Cell-type-specific ferroptosis programs were analyzed at the mouse level, and receiver-specific NicheNet analysis nominated immune signals linked to intestinal-cell responses. Functional relevance was tested using the ferroptosis inhibitor Liproxstatin-1 and rosiglitazone, a thiazolidinedione used as a pharmacological ACSL4 inhibitor. Three public intestinal transcriptomic datasets and biopsies from 2 patients with grade IV intestinal aGVHD provided human validation.
Results:
Bulk RNA sequencing of small-intestinal tissues collected on day +4 (n=5/group) identified 2,185 differentially expressed genes and a coordinated ferroptosis-related shift, including 44 upregulated validated ferroptosis drivers and 26 downregulated validated suppressors. Representative regulators of key ferroptosis processes changed coordinately: Acsl4 and Alox15 (polyunsaturated phospholipid remodeling), Ptgs2 and Duox1 (lipid oxidation and oxidative-inflammatory stress), and Hmox1 (iron and oxidative stress) increased, whereas the defense genes Gpx4, Gstm1, and Slc47a1 decreased. Complementary tissue analyses showed that intestinal ferrous iron, lipid peroxide, and malondialdehyde (MDA) levels were 55%, 63%, and 186% higher, respectively (P=.024, .026, and .003). MDA is a lipid-peroxidation end product; immunohistochemistry confirmed accumulation of another such product, 4-hydroxynonenal (4-HNE). Acsl4 mRNA and ACSL4 protein were increased, consistent with enhanced formation of oxidizable polyunsaturated phospholipids, whereas GPX4, the central enzyme for phospholipid-hydroperoxide detoxification, was reduced. COX2 (encoded by Ptgs2), an inducible lipid-metabolism enzyme associated with inflammatory and ferroptotic stress, was also increased, and mitochondria showed ultrastructural abnormalities consistent with ferroptosis.
scRNA-seq resolved 55,725 intestinal cells from 6 mice. Mouse-level analysis identified higher ferroptosis imbalance, defined as the difference between standardized pro-ferroptotic activation and antioxidant-defense scores, in fibroblasts, endothelial cells, and intestinal and vascular smooth muscle cells (nominal P=.006-.035; Benjamini-Hochberg q=.056-.091). Repair/regenerative program scores, reflecting epithelial repair and regeneration, were reduced across intestinal epithelial, absorptive, goblet, Paneth, and stem/transit-amplifying compartments (q=.036-.041). Across 4 intestinal receiver populations, interferon-gamma (IFNG) ranked first in the complete NicheNet analysis and all 6 leave-one-mouse-out reruns. IFNG expression in activated T-cell states, IFNGR1/IFNGR2 expression in receiver cells, induction of STAT1/IRF1/CXCL10/SOD2, and Acsl4 upregulation supported a reproducible IFNG-linked, ACSL4-associated ferroptosis-susceptibility state.
Liproxstatin-1 reduced intestinal lipid peroxidation, restored GPX4 expression, decreased COX2 and 4-HNE, attenuated colon, lung, and liver injury, and improved day-35 survival (9/13 vs 0/5; log-rank P=.0026). Pharmacological ACSL4 inhibition with rosiglitazone also improved survival (9/15 vs 1/10; P=.0009) and reduced colon and lung injury. ACSL4 expression was elevated in 3 independent human intestinal aGVHD datasets (P=.018 to <.001), and ACSL4 and 4-HNE were detected in both patient biopsies.
Conclusions:
ACSL4-associated ferroptosis constitutes a cell-type-restricted, immune-linked intestinal tissue-injury program in aGVHD. Its reproducible association with IFNG-responsive intestinal-cell states, together with protection by direct ferroptosis blockade and pharmacological ACSL4 inhibition, supports tissue-directed ferroptosis modulation as a therapeutic strategy complementary to systemic immunosuppression.
DISCLOSURES
Xianbo Huang, MD: No relevant conflicts of interest to declare.